Ina-Maria Rudolph

Ina-Maria Rudolph

Auto-generated profile, based on publicly available information

Ina-Maria Rudolph

Molecular Cardiovascular Research, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
AGAnna K. Greda
Anna K. Greda
JGJemila P. Gomes
Jemila P. Gomes
VSVanessa Schmidt-Krueger
Vanessa Schmidt-Krueger
EZEwa Zurawska-Plaksej
Ewa Zurawska-Plaksej
RFRaphaela Fritsche-Guenther
Raphaela Fritsche-Guenther
TWThomas E. Willnow
Thomas E. Willnow
Sortilin (SORT1) is a lipoprotein receptor that shows genome-wide association with hypercholesterolaemia, explained by its ability to control hepatic output of lipoproteins. Although SORT1 also shows genome-wide association with Alzheimer disease and frontotemporal lobe dementia, the most prevalent forms of age-related dementias, sortilin’s contribution to human brain lipid metabolism and health remains unclear. Here we show that sortilin mediates neuronal uptake of polyunsaturated fatty acids carried by apolipoprotein E (apoE). Using humanized mouse strains and induced pluripotent stem cell-based cell models of brain lipid homeostasis, we demonstrate that internalized lipids are converted into ligands for peroxisome proliferator-activated receptor alpha inducing transcription profiles that enable neurons to use long-chain fatty acids as metabolic fuel when glucose is limited. This pathway works with apoE3 but cannot operate with the Alzheimer disease risk factor apoE4, which disrupts sortilin’s endocytic activity. Our data indicate a role for the lipoprotein receptor sortilin in metabolic fuel choice in neurons, which may be crucial when glucose supply is limited, such as in the ageing brain.

10 September 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
KJKristian Juul‐Madsen
Kristian Juul‐Madsen
IRIna‐Maria Rudolph
Ina‐Maria Rudolph
JGJemila P. Gomes
Jemila P. Gomes
KMKatrina Meyer
Katrina Meyer
POPeter L. Ovesen
Peter L. Ovesen
TWThomas E. Willnow
Thomas E. Willnow
INTRODUCTION: Mutations in SORL1 , encoding the sorting receptor Sortilin‐related receptor with A‐type repeats (SORLA), are found in individuals with Alzheimer's disease (AD). We studied SORLA N1358S , carrying a mutation in its ligand binding domain, to learn more about receptor functions relevant for human brain health. METHODS: We investigated consequences of SORLA N1358S expression in induced pluripotent stem cell (iPSC)‐derived human neurons and microglia, using unbiased proteome screens and functional cell assays. RESULTS: We identified alterations in the SORLA N1358S interactome linked to biogenesis of exosomes. Consequently, the mutant receptor failed to promote release and neurotrophic qualities of exosomes, a defect attributed to altered exosomal content of microRNAs controlling neuronal maturation. DISCUSSION: We identified a role for SORLA in controlling quantity and neurotrophic quality of exosomes secreted by cells, suggesting impaired cellular cross talk through exosomes as a pathological trait contributing to AD pathology in carriers of SORL1 variants. Highlights: Familial Alzheimer's disease mutation in SORL1 changes interactome of mutant Sortilin‐related receptor with A‐type repeats (SORLA). Mutant SORLA impairs release of exosomes from neurons and microglia. Mutant exosomes lack neurotrophic qualities. Defect linked to alterations in microRNA content.